US FDA adds ‘boxed warning’ for Amgen’s Prolia drug that promotes bone mass loss

The U.S. Food and Drug Administration has added a serious warning regarding information about prescribing Amgen’s drug Prolia to treat bone loss because it increases the risk of dramatically low calcium levels in some patients.

Share This Post:

POPULAR POSTS
FOLLOW US
Like Us On Facebook
Follow Us On Twitter
Subscribe To Our Channel
TikTok
LIVE STREAM